TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Smartphone and 3D Printing Based Home Rehabilitation System for Chronic Stroke

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Individuals in the intervention all had a history of stroke.~Inclusion Criteria for feasibility study:~1. at least 18 years of age and living in the community~2. had a history of one stroke six or more months previous~3. had a minimum score of 124 on the Mattis Dementia Rating Scale (MDRS).~Exclusion Criteria for feasibility study:~1. acute or chronic pain that would interfere with participation~2. severely limited range of motion or contractures of shoulder, elbow, wrist or hand,~3. absent or severely impaired proprioception of the upper limb~4. musculoskeletal or circulatory conditions affecting the upper limb such as vascular disease, tendonitis, cellulitis, Raynaud's syndrome, or severe osteoarthritis or rheumatoid arthritis~5. spasticity graded as 3 or greater for upper extremity movement on the Modified Ashworth Scale (MAS)~6. botulinum toxin injections for spasticity management within three months of starting the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mRehab (Type: EXPERIMENTAL): Use of mRehab in a home program completing unilateral and bilateral activities. Participants are able to complete unilateral activities with their paretic arm/hand
- mRehab completing all activities bilaterally (Type: EXPERIMENTAL): Use of mRehab in a home program completing unilateral and bilateral activities. Participantsare can only complete intended unilateral activities using both hands

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Therapy in Liver Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Decompensated Cirrhosis of liver irrespective of etiology~Exclusion Criteria:~* Acute on chronic liver failure (fulfilling either APASL or CANONIC criteria of ACLF)~* Splenic diameter of more than 18 cm~* Concomitant HCC or other active malignancy~* Upper gastrointestinal bleeding in the previous 7 days~* Portal vein thrombosis~* Severe renal dysfunction as defined by creatnine \> 1.5mg/dl~* Severe cardiac dysfunction~* Uncontrolled diabetes (Hb A 1c ≥ 9) or diabetic retinopathy~* Acute infection or disseminate intravascular coagulation~* Active alcohol abuse in last 3 months~* Known hypersensitivity to GH~* HIV co-infection~* Pregnancy~* Refusal to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Standard Medical Therapy (Type: ACTIVE_COMPARATOR): Standard medical therapy: diuretics, lactulose, rifaximin, diuretics, albumin infusion, nutritional support (as required)
- Growth hormone (Type: ACTIVE_COMPARATOR): Growth Hormone: GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (based on IGF-1 levels) subcutaneously for 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of one of the following complicated skin and skin structure infections with MRSA (Methicillin-resistant Staphylococcus Aureus) either suspected or confirmed as the major cause of the infection:~  * major abscess requiring surgical incision and drainage;~ * infected burn (see exclusion criteria for important qualifications);~ * deep/extensive cellulitis;~ * infected ulcer (see exclusion criteria for important qualifications);~ * wound infections~* Patients must be expected to require at least 7 days of intravenous antibiotic treatment.~Exclusion Criteria:~* Received more than 24 hours of potentially effective systemic (IV/IM or PO) antibiotic therapy~* Burns involving \> 20% of body surface area or third degree/full thickness in nature, diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fasciitis, gas gangrene, or mediastinitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telavancin (Type: EXPERIMENTAL): None
- Vancomycin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trazodone and Its Augmentation With Pregabalin in the Treatment of Fibromyalgia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients diagnosed of fibromyalgia according to the American College of Rheumatology criteria~* written, informed consent~* able to understand and comply with the requirements of the study~Exclusion Criteria:~* pregnancy or breastfeeding~* unwillingness to discontinue other prescribed medications before entering in the study~* patients who had previously received trazodone without improvement or who did not tolerate the drug~* patients who had previously received pregabalin without improvement or who did not tolerate the drug (only for the phase II of the study)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- one arm study (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Laboratory-confirmed HIV~* Written informed consent~* Adults 20-59 years of age~Exclusion Criteria:~* Allergies to eggs, thimerosal or gentamicin sulphate~* Life-threatening reaction to previous Flu vaccine~* Bleeding disorder~* Pregnancy~* Receipt of blood or blood products in past 3 months~* Chronic illness~* Previous lab-confirmed H1N12009 infection~* Receipt of any non-study H1N12009 or Seasonal Influenza vaccine for 2009/10

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- One Dose Influenza vaccine (Type: ACTIVE_COMPARATOR): Arepanrix H1N1 Influenza vaccine (one dose)
- Two Doses Influenza vaccine (Type: ACTIVE_COMPARATOR): Arepanrix H1N1 Influenza vaccine (2 doses, 3 weeks apart)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Enamel Demineralization by Use of K18-smooth Surface Sealant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Orthodontic patients at the Department of Orthodontics Clinic, School of Dental Medicine, University of Colorado who agree to consent to this study.~* Orthodontic treatment plans that include fixed appliances from the second premolar to second premolar in both arches.~* Orthodontic treatment plans that include extractions of at least 3 bicuspids at about 1 month after bracket placement.~* The patient has adequate oral hygiene~Exclusion Criteria:~* Evidence of decalcification or restorations on any of the premolars planned for extraction prior to orthodontic treatment,~* Pregnant women (self reported)~* Any condition that contraindicates orthodontic treatment,~* Not willing to consent to the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 89 Years
- Healthy Volunteers: t

Study Arms:
- UDMA-K18 (Type: EXPERIMENTAL): UDMA-K18 smooth surface sealant
- UDMA-control (Type: PLACEBO_COMPARATOR): UDMA smooth surface sealant without K18
- Negative control (Type: NO_INTERVENTION): No intervention to provide baseline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age, \>18 years, AND~* Capable of understanding the purpose and risks of the study and have provided a signed and dated written IC, AND~* Prior to the study baseline, been treated with oral steroid medication, of which \> 2 weeks on oral prednisone equivalent of at least 40mg/day, and still have:~  * active ulcerative colon disease documented by a MAYO score of 6-11, and~ * active ulcerative colon disease documented by a MTWSI score of 7-15~OR~* Prior to the study baseline, documented clinical inability to decrease or stop the course of oral steroid medication. Subjects have been treated for a minimum of 12 weeks, and still have:~  * chronic active ulcerative colon disease documented by a MAYO score of 6-11, and~ * chronic active ulcerative colon disease documented by a MTWSI score of 7-15~OR~* Prior to the study baseline, been treated with a stable dosage of azathioprine for a minimum of 12 weeks, and have a moderate to severe relapse defined as:~  * chronic active ulcerative colon disease documented by a MAYO score of 6-11, and~ * chronic active ulcerative colon disease documented by a MTWSI score of 7-15.~Exclusion Criteria:~* UC, requiring immediate surgical, endoscopic, or radiological intervention; including massive haemorrhage, perforation and sepsis, suppurative complications (intra-abdominal or peri-anal abscesses) or toxic colon,~* history of large bowel surgery,~* history of serious infections,~* positive stool cultures, including Clostridium difficile,~* significant organ dysfunction,~* pregnancy, nursing mothers, or women of childbearing potential without appropriate use of contraceptives,~* treatment with:~  1. an altered dose of any 5-ASA preparation within 4 weeks of screening,~ 2. an altered dose of azathioprine or mercaptopurine within 4 weeks of screening (stable dosage of immunosuppressives is allowed), or start of azathioprine in the last 3 months prior to baseline,~ 3. probiotics, antibiotics within 1 month, methotrexate or cyclosporine within 2 months prior to screening,~ 4. any experimental treatment for this population e.g. infliximab, tacrolimus, FK506 or other anti TNFα therapy) within 2 months of screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): BIAP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Encouraging Mail Order Pharmacy Use to Improve Outcomes and Reduce Disparities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes patients who are users of CVD risk factor medications (antihypertensive therapies, antihyperlipidemics therapies, and oral antihyperglycemic therapies),~* Diabetes patients considered to be poorly adherent to CVD risk factor medications within the prior 12 months~* Diabetes patients who have not used the mail order pharmacy to fill any prescribed medications at least once in the prior 12 months~Exclusion Criteria:~* Pregnancy or Dementia/Traumatic Brain Injury diagnosis in the prior 12 months~* Hospitalized, in Skilled Nursing Facility, Hospice, or Home Health at the time of randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standardized intervention (Type: EXPERIMENTAL): Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
- Usual care (Type: EXPERIMENTAL): Usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. At least 18 years of age.~2. Clinical diagnosis of Systemic Lupus Erythematosus (SLE) by ACR criteria.~3. Active SLE disease.~4. Autoantibody-positive.~5. On stable SLE treatment regimen which may include corticosteroids (for example, prednisone), antimalarial (for example, hydroxychloroquine) and/or immunosuppressants (for example, azathioprine, methotrexate, mycophenolate, etc.)~Exclusion Criteria:~1. Pregnant or nursing.~2. Have received treatment with any B cell targeted therapy (for example, rituximab or belimumab).~3. Have received treatment an investigational biological agent in the past year.~4. Have received intravenous (IV) cyclophosphamide within 90 days of Day 0.~5. Have severe active lupus kidney disease.~6. Have severe active central nervous system (CNS) lupus.~7. Have required management of acute or chronic infections within the past 60 days.~8. Have current drug or alcohol abuse or dependence.~9. Have a positive test for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.~10. Have a history of hypersensitivity reactions to contrast agents or biological medicines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo plus standard therapy (Type: PLACEBO_COMPARATOR): Placebo SC plus standard therapy; placebo administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo subjects who opt to participate will receive belimumab 200 mg SC weekly for an additional 6-months.
- Belimumab 200 mg SC plus standard therapy (Type: EXPERIMENTAL): Belimumab 200 mg SC plus standard therapy; belimumab administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, subjects who opt to participate will continue on the same dose of belimumab for an additional 6-months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Postural Study Comparing Sitting on the Floor Versus Sitting in a Chair While Playing Video Games.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English and Spanish Speaking~Exclusion Criteria:~* Non-english or non-spanish speaking

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Sitting in a chair (Type: OTHER): Sitting in a chair with back support and feet flat on the ground
- Sitting on the Floor (Type: OTHER): Sitting on the floor without back support, crossed leg style

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medtronic Minimed Overnight Closed-Loop System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for the study, a subject must meet the following criteria:~* Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year and a Medtronic insulin infusion pump for at least 3 months The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not required.~* Age 10.0 - 35 years~Exclusion Criteria:~The presence of any of the following is an exclusion for the study:~* Diabetic ketoacidosis in the past month~* Hypoglycemic seizure or loss of consciousness in the past 3 months~* History of seizure disorder (except for hypoglycemic seizure)~* History of any heart disease including coronary artery disease, heart failure, or arrhythmias~* Cystic fibrosis~* Current use of oral/inhaled glucocorticoids, beta-blockers or other medications, which in the judgment of the investigator would be a contraindication to participation in the study.~* History of ongoing renal disease (other than microalbuminuria).~* Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as:~  * Inpatient psychiatric treatment in the past 6 months~ * Uncontrolled adrenal disorder~ * Abuse of alcohol~* Pregnancy

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Inpatient overnight (Type: EXPERIMENTAL): Participants in this group will have an overnight evaluation to test safety of the closed-loop system therapy device.
- Summer Camp Session (Type: EXPERIMENTAL): Participants in this group will receive either the sensor augmented pump or the close loop controller on the first night, then alternated treatment type each night for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PC-Based Cognitive Rehabilitation for Traumatic Brain Injury (TBI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: ECOLOGIC_OR_COMMUNITY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Control subjects were required to meet the following inclusion criteria:~* (a) fluency in the English language~* (b) no current or prior history of bipolar disorder, mania, or schizophrenia~* (c) no current substance abuse~* (d) no concurrent history of neurologic disease known to affect cognitive functioning~* (e) on a stable dosage of any required medication~* (f) auditory functioning sufficient to understanding normal conversational speech and visual acuity normal or corrected to 20/40 or better~Exclusion criteria:~* History of TBI~Exclusion Criteria for TBI patients:~* TBI patients had to meet the same inclusion criteria as the controls with the exception that they were required to have a history of TBI. They also had to be in the chronic phase, i.e., 1-4 yrs post-injury.~* Exclusion criteria:~  * current substance abuse~ * current psychiatric diagnosis other than PTSD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: t

Study Arms:
- Control subjects (Type: None): Control subjects = 237. These subjects underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
- TBI patients (Type: None): TBI patients N = 28. These patients underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Development of An Exergame for Caregivers of Individuals With Alzheimer's Disease or Related Dementias

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Be 18 years or older~* Be a caregiver who spends a significant amount of time with a family member, partner, or friend with Alzheimer's Disease or related dementias.~* Be able to walk for at least 20 minutes at a time~* Have regular access to an Android smartphone with Internet access~* Be comfortable wearing a fitness tracker for the duration of the study~* Must be located in Massachusetts, New Hampshire, Rhode Island, Connecticut, or New York City~Exclusion Criteria:~* A recent (within the past 6 months) cardiovascular event or fall.~* A score on the Short Portable Mental Status Questionnaire (SPMSQ) that indicates intellectual impairment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Exergame Experience (Type: EXPERIMENTAL): Participants will use the exergame for 6 weeks, during which time game telemetry data (all interactions with the software) will be automatically logged by the system. The participants will be asked to use the game at least every other day. Caregivers will be sent an email or text message to remind them to use the system if they have not done so within three days. Utilizing two-way text messaging, an experience sampling protocol will be employed: once per week, participants will be sent brief questions probing their level of satisfaction with the exergame and their level of perceived connectedness to the community of other caregivers using the exergame.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete